Spinal FrontiersPowered by NSpineWeekly alert sign-up
← Back

Spinal Frontiers · Safety in Focus

Safety in Focus

When a safety story spreads, the official sources, a short summary and what is still unknown, in one place for clinicians.

Current briefings

Last checked 8 November 2026Safety in Focus

Zolgensma and tumour reports

The FDA is investigating tumours after Zolgensma gene therapy for SMA; two are confirmed as caused by the vector inserting next to the GLI1 gene. Official sources, summary and what is unknown.

Read the briefing →

About Safety in Focus

When a safety story about a medicine, device or therapy that spine teams meet starts to spread, we put the official sources in one place, with a short summary, what is still unknown and where to report. Each briefing says who it is written for.

  • Official sources first: regulators and manufacturers, then national clinical bodies and patient organisations, then published papers.
  • AI-assisted summary: each summary is drafted with the help of AI and read by an editor. It is labelled as such and may contain errors, so always check the original sources and use your own judgement.
  • Patients and families: these pages are written for clinicians. Talk to your treating team before acting on anything here.
  • Updates: every briefing is re-checked each week and shows the date it was last checked.

For device recalls and safety notices, see Regulatory Watch. To report a problem, see Report a Device Problem. Corrections and suggestions: spinalfrontiers@nspine.com.

Spinal Frontiers is published by NSpine Limited, registered in England and Wales (company no. 08362634), 14 Park Row, Nottingham NG1 6GR, United Kingdom. Every item is summarised in our own words and links to its original source. Listings are a selection made at NSpine's editorial discretion and are not exhaustive; inclusion is not an endorsement, and omission implies nothing. Sponsors and advertisers have no influence on what we cover. Nothing here is medical, legal or financial advice. Spotted an error or a broken link? Email spinalfrontiers@nspine.com, or use the feedback page.

Spinal Frontiers is a trademark of NSpine GmbH.

Information only, summarised from third-party sources: not medical, legal, regulatory or financial advice. Full disclaimer.

© 2013 – 2026 NSpine Limited. Privacy notice.